Novel serology testing for sporadic inclusion body myositis: Disease-specificity and diagnostic utility

Current Opinion in Rheumatology

Volumn 27, Issue 6, 2015, Pages 595-600

  Herbert, Megan K ^a   Pruijn, Ger J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Auto antibodies; Cytoplasmic 5' nucleotidase 1A; Diagnosis; Sporadic inclusion body myositis

Indexed keywords

5' NUCLEOTIDASE; AUTOANTIBODY; CYTOSOLIC 5' NUCLEOTIDASE 1A; EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; INCLUSION BODY MYOSITIS; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; SEROLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; MYOSITIS, INCLUSION BODY; SENSITIVITY AND SPECIFICITY;

5'-NUCLEOTIDASE; AUTOANTIBODIES; HUMANS; MYOSITIS, INCLUSION BODY; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS;

EID: 84942516564     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000216     Document Type: Article

References (22)

1. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013; 88:83-105.
2. Mammen AL. Necrotizing myopathies: beyond statins. Curr Opin Rheumatol 2014; 26:679-683.
3. Vattemi G, Mirabella M, Guglielmi V, et al. Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. Autoimmun Highlights 2014; 5:77-85.
4. Brady S, Squier W, Sewry C, et al. A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis. Br Med J Open 2014; 4:e004552.
5. Gran Pina Cruellas M, Dos Santos Trindade Viana V, Levy-Neto M, et al. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo) 2013; 68:909-914.
6. Koenig M, Fritzler M, Targoff I, et al. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9:R78.
7. Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, et al. Anti-PL-7 (antithreonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine 2012; 91:206-211.
8. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the antisynthetase syndrome: a comprehensive review. Autoimmun Rev 2014; 13:367-371.
9. Nakashima R, Imura Y, Hosono Y, et al. The multicenter study of a new assay for simultaneous detection of multiple antiaminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS One 2014; 9:e85062.
10. Betteridge Z, Gunawardena H, North J, et al. Antisynthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 2007; 46:1005-1008.
11. Ghirardello A, Zampieri S, Iaccarino L, et al. Anti-Mi-2 antibodies. Autoimmunity 2005; 38:79-83.
12. Tsuji T, Toru A, Sugimoto C, et al. The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease. Eur Respir J 2014; 44; Suppl 58, P714.
13. Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66:1345-1349.
14. Bodoki L, Nagy-Vincze M, Griger Z, et al. Four dermatomyositis-specific autoantibodies - anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5 - in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev 2014; 13:1211-1219.
15. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 kDa muscle protein in inclusion body myositis. PLoS One 2011; 6:e20266.
16. Pluk H, van Hoeve BJA, van Dooren SHJ, et al. Autoantibodies to cytosolic 50-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73:397-407.
17. Larman BH, Salajegheh M, Nazareno R, et al. Cytosolic 50-nucleotidase1 A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73:408-418.
18. El-Shammaa NA, Fishbein WN, Armbrustmacher VW. Interstitial 5'-nucleotidase stain for frozen biopsy specimens of skeletal muscle. A useful adjunct in the diagnosis of polymyositis. Arch Pathol Lab Med 1984; 108:251-256.
19. Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, et al. Cytosolic 5'-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseases. Arthritis Care Res 2015. [Epub ahead of print]
20. Goyal NA, Cash TM, Alam U, et al. Seropositivity for NT5c1 Aantibody insporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement. J Neurol Neurosurg Psychiatry 2015. [Epub ahead of print]
21. Greenberg SA. Cytoplasmic 50-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utility. Muscle Nerve 2014; 50:488-492.
22. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, et al. Disease specificity of autoantibodies to cytosolic 50-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2015. [Epub ahead of print]